In summary, the six-marker panel with HOXD13, SFN, RASSF1a, P16, PCDHGB7, and hMLH1 exhibits significantly aberrant methylation in serum cfDNA from breast cancer patients compared with both age-matched healthy women and women with a benign breast disease. Here, MLH1 is linked to breast carcinoma.